Cutaneous melanoma, historically a rare disease, has continued to see increased incidence over the past several decades. Fortunately, this has been accompanied by increased understanding of the pathobiology, leading to the development of immunotherapy and targeted therapies. In this activity, melanoma specialist Jason J. Luke, MD, FACP, discusses the impact of evolving therapies on the disease burden, survival, and treatment tolerability by patients with cutaneous melanoma. Recent clinical trial results and guideline updates for both perioperative and metastatic cutaneous melanoma are reviewed. To provide patient-centric care, Dr. Luke shares his expert insights and recommendations for individualizing treatment selection and sequencing, as well as providing supportive care and adverse event management.

Presenting Faculty

• 

  Jason J. Luke, MD, FACP

  Hematology/Oncology
  Associate Professor of Medicine
  Director of Cancer Immunotherapeutics Center
  University of Pittsburgh School of Medicine
  Pittsburgh, Pennsylvania